SCHEMBL17876010

SCHEMBL17876010

O=S1(=O)Cc2ccc(-c3cc(-c4ccccc4)cc(-c4ccccc4)c3)cc2-c2cc(-c3cc(-c4cccnc4)cc(-c4cccnc4)c3)ccc2C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 2/20 0.52
CYP11B1 P15538 10/20 0.48
CYP11B2 P19099 10/20 0.48
CYP19A1 P11511 4/20 0.48
CYP1A2 P05177 4/20 0.47
CYP2C9 P11712 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
CYP17A1 P05093 1/20 0.44
MKNK1 Q9BUB5 2/20 0.43
MKNK2 Q9HBH9 2/20 0.43
KDM1A O60341 1/20 0.42
DHODH Q02127 1/20 0.41
KMO O15229 1/20 0.41
TYRO3 Q06418 1/20 0.41
NTRK2 Q16620 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
TBXAS1 P24557 1/20 0.41
PDE3B Q13370 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17876012 0.96 TDP2 (0.52) TDP2CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL17875957 0.95 TDP2 (0.51) TDP2CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL17875964 0.95 TDP2 (0.51) TDP2CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL17876014 0.91 CYP19A1 (0.56) TDP2CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL17875969 0.91 CYP11B1 (0.52) TDP2CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL17875974 0.87 CYP19A1 (0.51) TDP2CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL17875965 0.87 CYP19A1 (0.51) TDP2CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL17876009 0.87 TYRO3 (0.47) TDP2CYP3A4DHODHKMOTYRO3
SCHEMBL17875997 0.84 CYP19A1 (0.41) TDP2CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL17876001 0.84 PGR (0.41) TDP2CYP11B1CYP11B2CYP19A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-03-03 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CRY2, CCNE2 TDP2 3979/4885CYP11B1 938/4885CYP11B2 1374/4885
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNE2 TDP2 3979/4885CYP11B1 938/4885CYP11B2 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.